These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23963211)

  • 1. Reinventing bioinnovation.
    Kaitin KI; Honig PK
    Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PCAST report on pharmaceutical innovation: implications for the FDA.
    Woodcock J
    Clin Pharmacol Ther; 2013 Sep; 94(3):297-300. PubMed ID: 23963215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A forensic analysis of drug targets from 2000 through 2012.
    Munos B
    Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of original research contributions toward FDA-approved drugs.
    Patridge EV; Gareiss PC; Kinch MS; Hoyer DW
    Drug Discov Today; 2015 Oct; 20(10):1182-7. PubMed ID: 26113307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making translation work.
    Williams RS; Desmond-Hellmann S
    Science; 2011 Jun; 332(6036):1359. PubMed ID: 21680815
    [No Abstract]   [Full Text] [Related]  

  • 8. The PCAST report: impact and implications for the pharmaceutical industry.
    Morris SA; Rosenblatt M; Orloff JJ; Lewis-Hall F; Waldstreicher J
    Clin Pharmacol Ther; 2013 Sep; 94(3):300-2. PubMed ID: 23963216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development: Time for teamwork.
    May M
    Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract]   [Full Text] [Related]  

  • 10. Industry and regulatory performance in 2012: a year in review.
    Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
    Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European lead factory opens for business.
    Mullard A
    Nat Rev Drug Discov; 2013 Mar; 12(3):173-5. PubMed ID: 23449292
    [No Abstract]   [Full Text] [Related]  

  • 12. Traditional drug-discovery model ripe for reform.
    Cressey D
    Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
    [No Abstract]   [Full Text] [Related]  

  • 13. Open innovation and intellectual property: time for a reboot?
    Judd DB
    Drug Discov Today; 2013 Oct; 18(19-20):907-9. PubMed ID: 23958455
    [No Abstract]   [Full Text] [Related]  

  • 14. Medicines discovery in the 21st century: the case for a stakeholder corporation.
    Dixon J; England P; Lawton G; Machin P; Palmer A
    Drug Discov Today; 2010 Sep; 15(17-18):700-3. PubMed ID: 20678583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining Manufacturing Readiness for Breakthrough Drug Development.
    Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
    AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
    [No Abstract]   [Full Text] [Related]  

  • 16. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 18. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 19. New frontiers for collaborative research.
    Goldman M
    Sci Transl Med; 2013 Dec; 5(216):216ed22. PubMed ID: 24353157
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
    Kaitin KI; DiMasi JA
    Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.